LENZ Therapeutics, Inc. (LENZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.96+2.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LENZ
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | 19.1 | — | — | — | — | — |
| Cost of Revenues | — | 0.4 | — | — | — | — | — |
| Operating Expenses & Income | |||||||
| Selling, General & Admin | 151.6 | 91.1 | 28.8 | 12.9 | — | — | — |
| R&D Expenses | — | 18.7 | 29.8 | 59.5 | 72.8 | 37.9 | 9.1 |
| Operating Income | (135.7) | (91.1) | (58.6) | (72.4) | (105.6) | (60.4) | (13.5) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 10.1 | 9.8 | 8.6 | 2.2 | — | — | — |
| Other Non-Operating Income / Expenses | 9.7 | 9.5 | 8.8 | 2.3 | 4.6 | (10.3) | (54.9) |
| EBT, Incl. Unusual Items | — | (81.6) | (49.8) | (70.1) | — | — | — |
| Income Tax Expense | — | 0.5 | 0.0 | (0.2) | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (126.0) | (82.1) | (49.8) | (70.0) | (101.1) | (70.8) | (68.4) |
| Per Share | |||||||
| Basic EPS | (4.02) | (2.85) | (2.34) | (35.71) | (1.84) | (2.45) | — |
| Diluted EPS | (4.02) | (2.85) | (2.34) | (35.71) | (1.84) | (2.45) | — |
| Basic Weighted Avg Shares | 31.4 | 28.8 | 21.3 | 2.0 | 54.9 | 28.9 | — |
| Diluted Weighted Avg Shares | 31.4 | 28.8 | 21.3 | 2.0 | 54.9 | 28.9 | — |
| Supplemental | |||||||
| EBITDA | — | (90.9) | (58.6) | (70.0) | (103.3) | (59.7) | (13.4) |
| EBIT | (135.7) | (91.1) | (58.6) | (72.4) | (105.6) | (60.4) | (13.5) |
| Effective Tax Rate | — | — | — | 0.3% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.